- Home
- VTVT
as 11-20-2025 3:58pm EST
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HIGH POINT |
| Market Cap: | 54.4M | IPO Year: | 2015 |
| Target Price: | $37.00 | AVG Volume (30 days): | 11.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.15 - $33.16 | Next Earning Date: | 11-06-2025 |
| Revenue: | $17,000 | Revenue Growth: | -98.30% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest vTv Therapeutics Inc. News
VTVT Breaking Stock News: Dive into VTVT Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
BTIG Research Initiates Coverage on vTv Therapeutics With Buy Rating, $40 Price Target
Zacks
13 days ago
All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy
Associated Press Finance
17 days ago
VTv Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
17 days ago
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
GlobeNewswire
5 months ago
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
MT Newswires
6 months ago
vTv Therapeutics Names Michael Tung as Finance Chief
GlobeNewswire
6 months ago
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
Compare VTVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTVT vTv Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.